Browsing Tag
Donanemab
2 posts
Eli Lilly (NYSE: LLY) to acquire AtaiBeckley in $3.8bn TRD psychedelic deal
Eli Lilly (NYSE: LLY) to acquire AtaiBeckley for $6.75/share cash plus $2.50 CVR, taking the BPL-003 5-MeO-DMT depression asset to Phase 3 read in 2029.
UK approves Lilly’s Alzheimer’s drug but labels it ‘too expensive’ for NHS use
The UK has approved Eli Lilly’s new Alzheimer’s treatment, donanemab, which has shown promise in slowing cognitive decline.…